A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)

Researchers are looking for new ways to treat muscle-invasive bladder cancer (MIBC). MIBC is a type of bladder cancer that has spread into the muscle layer of the bladder but has not spread to other distant parts of the body. The usual treatment for MIBC is surgery to remove the bladder but some people choose to have other treatments, such as chemoradiotherapy (CRT), instead of surgery so they can keep their bladder. Researchers want to know if giving 2 trial treatments with CRT can treat MIBC. One trial treatment is called sacituzumab tirumotecan (sac-TMT) and the other trial treatment is c

Trial Details

NCT ID
NCT07829783
Phase
PHASE3
Sponsor
Merck Sharp & Dohme LLC
Status
RECRUITING
Cancer Type
Bladder Cancer
Interventions
  • Sac-TMT
  • Pembrolizumab and Berahyaluronidase alfa
  • Cisplatin
  • 5-FU
  • MMC
  • Capecitabine
Locations (sample)
  • Kaohsiung City, Taiwan|22.61626,120.31333
  • Cherkasy, Cherkasy Oblast, Ukraine|49.44452,32.05738
  • Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine|48.92312,24.71248
  • Kropyvnytskyi, Kirovohrad Oblast, Ukraine|48.50834,32.26618
  • Lviv, Lviv Oblast, Ukraine|49.83826,24.02324

Key Eligibility Criteria

  • The main inclusion criteria include but are not limited to the following:
  • Has a diagnosis of muscle-invasive bladder cancer (MIBC) (cT2-T4aN0-N1)
  • Has clinically nonmetastatic bladder cancer (N0-N1M0)
  • Is either ineligible for radical cystectomy or has opted for bladder preservation and is planned to receive chemoradiotherapy (CRT)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →